ALS Drug Fails Clinical Trial, Making Its Future Uncertain

Published on March 11, 2024

Relyvrio, a drug meant to treat amyotrophic lateral sclerosis (ALS), failed clinical trials due to not providing significant symptom relief in those suffering from the disease. In particular, the phase 3 clinical trial showed that the drug, which is a combination of sodium phenylbutyrate and taurursodiol, failed to improve patient symptoms after 48 weeks of treatment. Additionally, compared to a placebo, the medication was unable to significantly improve reported quality of life, overall survival, and respiratory function, CNN Health reported. “We are surprised and deeply disappointed by the [phase 3] results following the positive data from the CENTAUR trial,” Justin Klee and Joshua Cohen, co-CEOs of drug manufacturer Amylyx Pharmaceuticals, said in a press release. The Centaur trial was the phase 2 trial....

Continue reading on website
Other news

Trump Campaign Says Democrats Twisted Trump’s Words on Cutting Social Security

March 11, 2024
Former President Donald Trump said Monday that he believes there’s scope to save taxpayer dollars by cutting fraud and waste from entitlement programs, and then Democrats seized on his comments to claim that he backs slashing Social Security benefits, which the Trump campaign denied and accused Democrats of twisting his words.The future of entitlement programs has become a key political talking po

Liberals, Bloc Push Back on Tory Attempt to Probe Killers’ Transfers to Medium-Security Jail

March 11, 2024
An attempt by the Conservatives to launch an in-depth committee study into the transfer of notorious killers, such as Luka Magnotta, to medium-security prison has been quashed by Liberal and Bloc MPs.The Conservatives initiated a special meeting of the House of Commons public safety committee on March 11, following the recent news that Mr. Magnotta had been moved out of maximum-security in 2022. M